posted on 2016-02-19, 01:43authored byMarianne de Villiers, Cristiano Macuamule, Christina Spry, Yoo-Min Hyun, Erick Strauss, Kevin J. Saliba
Pantothenamides are secondary or
tertiary amides of pantothenic
acid, the vitamin precursor of the essential cofactor and universal
acyl carrier coenzyme A. A recent study has demonstrated that pantothenamides
inhibit the growth of blood-stage Plasmodium falciparum with submicromolar potency by exerting an effect on pantothenic
acid utilization, but only when the pantetheinase present in the growth
medium has been inactivated. Here, we demonstrate that small modifications
of the pantothenamide core structure are sufficient to counteract
pantetheinase-mediated degradation and that the resulting pantothenamide
analogues still inhibit the in vitro proliferation of P. falciparum by targeting a pantothenic acid-dependent process (or processes).
Finally, we investigated the toxicity of the most potent analogues
to human cells and show that the selectivity ratio exceeds 100 in
one case. Taken together, these results provide further support for
pantothenic acid utilization being a viable target for antimalarial
drug discovery.